<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018537</url>
  </required_header>
  <id_info>
    <org_study_id>20081794</org_study_id>
    <nct_id>NCT01018537</nct_id>
  </id_info>
  <brief_title>NARCOMS Registry: A Multiple Sclerosis Registry</brief_title>
  <acronym>NARCOMS</acronym>
  <official_title>NARCOMS Global Multiple Sclerosis Registry: A Long-Term Study to Facilitate Research in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Consortium of Multiple Sclerosis Centers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is based on the idea that we can learn about the complexities of MS by following
      disease and treatment patterns in a large group of people over several years. The information
      gathered is used for research only. Results are presented in summary form only. All details
      submitted by registry participants is strictly confidential.

      To participate in NARCOMS complete the baseline enrollment survey online through
      www.narcoms.org (or directly using the following link: http://j.mp/2jJm5lK) or you can
      request a mail-in survey be sent to you by emailing MSregistry@narcoms.org. You will be asked
      to update your information, online or by mail, twice a year. Each update survey typically
      takes less than 20 minutes to complete.

      There is no cost to participate. For your participation you are offered a free subscription
      to the NARCOMS quarterly magazine, NARCOMS Now. NARCOMS Now provides a reliable source of
      information about the latest in MS research and disease management. You can stop
      participating in the registry at any time.

      You may also receive additional surveys or information on clinical trials. You are not
      obligated to participate and these additional studies will always come directly from NARCOMS.
      Your contact information will not be shared or sold to other parties.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data coordinating center, located at Washington University, maintains NARCOMS, the worlds
      largest voluntary, patient driven MS registry. The registry involves personnel from at least
      three other sites in the US and Canada (Cleveland Clinic Foundation, University of Alabama at
      Birmingham, and the University of Manitoba in Canada). Over the past 20 years more than
      38,000 people with MS across the U.S., Canada and over 50 other countries, including over
      4,000 Veterans, have participated in the registry by submitting their health-related data by
      mail or online. Registry data have been featured in over 100 peer-reviewed journal articles,
      scientific posters and presentations. These reports have provided information to guide new
      research. They also provide evidence supporting the approval of new drugs in the fight
      against MS.

      The North American Research Committee on Multiple Sclerosis (NARCOMS) is supported in part by
      the Consortium of Multiple Sclerosis Centers (CMSC), a not-for-profit professional
      organization for multiple sclerosis (MS) healthcare providers and researchers involving 198
      participating centers of the MS treatment and research community.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 1996</start_date>
  <completion_date type="Anticipated">December 2050</completion_date>
  <primary_completion_date type="Anticipated">December 2050</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Disease progression over time of follow up</measure>
    <time_frame>up to 15 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contributing factors to change in MS disease status</measure>
    <time_frame>up to 15 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Medication usage in multiple sclerosis</measure>
    <time_frame>up to 15 years</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">50000</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals who have been diagnosed with multiple sclerosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any individual who has been diagnosed with multiple sclerosis or clinically isolated
             syndrome

          -  Must be at least 18 years of age

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J. Fox, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Mellen Center for MS / Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amber Salter, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tuula Tyry, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Dignity Health, St. Joseph's Hospital and Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary R Cutter, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruth Ann Marrie, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NARCOMS Team</last_name>
    <phone>1-800-253-7884</phone>
    <email>MSregistry@narcoms.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NARCOMS Team</last_name>
      <phone>800-253-7884</phone>
      <email>MSregistry@narcoms.org</email>
    </contact>
    <investigator>
      <last_name>Amber Salter, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.narcoms.org</url>
    <description>NARCOMS homepage where you can get more information or enroll in the registry.</description>
  </link>
  <link>
    <url>http://www.mscare.org</url>
    <description>Consortium of Multiple Sclerosis Centers (CMSC) homepage</description>
  </link>
  <reference>
    <citation>Mahajan ST, Patel PB, Marrie RA. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol. 2010 Apr;183(4):1432-7. doi: 10.1016/j.juro.2009.12.029. Epub 2010 Feb 20.</citation>
    <PMID>20171697</PMID>
  </reference>
  <reference>
    <citation>Buchanan RJ, Chakravorty BJ, Tyry T, Hatcher W, Vollmer T. Age-related comparisons of people with multiple sclerosis: demographic, disease, and treatment characteristics. NeuroRehabilitation. 2009;25(4):271-8. doi: 10.3233/NRE-2009-0525.</citation>
    <PMID>20037220</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Cutter G, Tyry T, Vollmer T. A cross-sectional study of bone health in multiple sclerosis. Neurology. 2009 Oct 27;73(17):1394-8. doi: 10.1212/WNL.0b013e3181beece8.</citation>
    <PMID>19858462</PMID>
  </reference>
  <reference>
    <citation>Hadjimichael O, Vollmer T, Oleen-Burkey M; North American Research Committee on Multiple Sclerosis. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008 Nov 14;6:100. doi: 10.1186/1477-7525-6-100.</citation>
    <PMID>19014588</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Smoking status over two years in patients with multiple sclerosis. Neuroepidemiology. 2009;32(1):72-9. doi: 10.1159/000170910. Epub 2008 Nov 12.</citation>
    <PMID>19001800</PMID>
  </reference>
  <reference>
    <citation>Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. Mult Scler. 2009 Jan;15(1):105-13. doi: 10.1177/1352458508096680. Epub 2008 Oct 9.</citation>
    <PMID>18845651</PMID>
  </reference>
  <reference>
    <citation>Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. 2008 Sep;14(8):1091-8. doi: 10.1177/1352458508092263.</citation>
    <PMID>18728060</PMID>
  </reference>
  <reference>
    <citation>Julian LJ, Vella L, Vollmer T, Hadjimichael O, Mohr DC. Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol. 2008 Sep;255(9):1354-60. doi: 10.1007/s00415-008-0910-y. Epub 2008 Jul 17.</citation>
    <PMID>18677639</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology. 2007 Jun 5;68(23):1971-8.</citation>
    <PMID>17548546</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: diagnosis. Mult Scler. 2007 Jul;13(6):770-5. Epub 2007 Mar 15.</citation>
    <PMID>17525097</PMID>
  </reference>
  <reference>
    <citation>Hadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain. 2007 Jan;127(1-2):35-41. Epub 2006 Sep 1.</citation>
    <PMID>16949751</PMID>
  </reference>
  <reference>
    <citation>Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006 Jun 13;66(11):1696-702.</citation>
    <PMID>16769943</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology. 2006 Apr 25;66(8):1235-40.</citation>
    <PMID>16636241</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Changes in the ascertainment of multiple sclerosis. Neurology. 2005 Oct 11;65(7):1066-70.</citation>
    <PMID>16217060</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: fatigue assessment. Mult Scler. 2005 Oct;11(5):583-4.</citation>
    <PMID>16193897</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Cutter G, Tyry T, Hadjimichael O, Vollmer T. Validation of the NARCOMS Registry: pain assessment. Mult Scler. 2005 Jun;11(3):338-42.</citation>
    <PMID>15957517</PMID>
  </reference>
  <reference>
    <citation>Lo AC, Hadjimichael O, Vollmer TL. Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry. Mult Scler. 2005 Feb;11(1):33-40.</citation>
    <PMID>15732264</PMID>
  </reference>
  <reference>
    <citation>Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004 Oct;10(5):589-95.</citation>
    <PMID>15471378</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Hadjimichael O, Vollmer T. Predictors of alternative medicine use by multiple sclerosis patients. Mult Scler. 2003 Oct;9(5):461-6.</citation>
    <PMID>14582770</PMID>
  </reference>
  <reference>
    <citation>Buchanan RJ, Radin D, Chakravorty BJ, Tyry T. Informal care giving to more disabled people with multiple sclerosis. Disabil Rehabil. 2009;31(15):1244-56.</citation>
    <PMID>19802928</PMID>
  </reference>
  <reference>
    <citation>Buchanan R, Radin D, Chakravorty BJ, Tyry T. Perceptions of informal care givers: health and support services provided to people with multiple sclerosis. Disabil Rehabil. 2010;32(6):500-10. doi: 10.3109/09638280903171485.</citation>
    <PMID>19852704</PMID>
  </reference>
  <reference>
    <citation>Finlayson M, Cho C. A descriptive profile of caregivers of older adults with MS and the assistance they provide. Disabil Rehabil. 2008;30(24):1848-57. doi: 10.1080/09638280701707324.</citation>
    <PMID>18608376</PMID>
  </reference>
  <reference>
    <citation>Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs. 2003 Jun;35(3):163-70.</citation>
    <PMID>12830664</PMID>
  </reference>
  <reference>
    <citation>Fraser C, Morgante L, Hadjimichael O, Vollmer T. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs. 2004 Jun;36(3):120-9.</citation>
    <PMID>15233411</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009 Jan 13;72(2):117-24. doi: 10.1212/01.wnl.0000333252.78173.5f. Epub 2008 Oct 29.</citation>
    <PMID>18971448</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010 Mar 30;74(13):1041-7. doi: 10.1212/WNL.0b013e3181d6b125.</citation>
    <PMID>20350978</PMID>
  </reference>
  <reference>
    <citation>Buchanan RJ, Minden SL, Chakravorty BJ, Hatcher W, Tyry T, Vollmer T. A pilot study of young adults with multiple sclerosis: demographic, disease, treatment, and psychosocial characteristics. Disabil Health J. 2010 Oct;3(4):262-70. doi: 10.1016/j.dhjo.2009.09.003. Epub 2009 Nov 26.</citation>
    <PMID>21122795</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. 2011 Aug;124(2):135-41. doi: 10.1111/j.1600-0404.2010.01436.x. Epub 2010 Sep 29.</citation>
    <PMID>20880264</PMID>
  </reference>
  <reference>
    <citation>Salter AR, Cutter GR, Tyry T, Marrie RA, Vollmer T. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin. 2010 Feb;26(2):493-500. doi: 10.1185/03007990903500649.</citation>
    <PMID>20014979</PMID>
  </reference>
  <reference>
    <citation>Buchanan RJ, Zuniga MA, Carrillo-Zuniga G, Chakravorty BJ, Tyry T, Moreau RL, Huang C, Vollmer T. Comparisons of Latinos, African Americans, and Caucasians with multiple sclerosis. Ethn Dis. 2010 Autumn;20(4):451-7.</citation>
    <PMID>21305836</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Horwitz R, Cutter G, Tyry T. Cumulative impact of comorbidity on quality of life in MS. Acta Neurol Scand. 2012 Mar;125(3):180-6. doi: 10.1111/j.1600-0404.2011.01526.x. Epub 2011 May 26.</citation>
    <PMID>21615355</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Smokers with multiple sclerosis are more likely to report comorbid autoimmune diseases. Neuroepidemiology. 2011;36(2):85-90. doi: 10.1159/000323948. Epub 2011 Feb 1.</citation>
    <PMID>21282965</PMID>
  </reference>
  <reference>
    <citation>Cutter GR, Zimmerman J, Salter AR, Knappertz V, Suarez G, Waterbor J, Howard VJ, Ann Marrie R. Causes of death among persons with multiple sclerosis. Mult Scler Relat Disord. 2015 Sep;4(5):484-490. doi: 10.1016/j.msard.2015.07.008. Epub 2015 Jul 18.</citation>
    <PMID>26346799</PMID>
  </reference>
  <reference>
    <citation>Bethoux F, Marrie RA. A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis. Patient. 2016 Dec;9(6):537-546.</citation>
    <PMID>27154536</PMID>
  </reference>
  <reference>
    <citation>Wang G, Marrie RA, Salter AR, Fox R, Cofield SS, Tyry T, Cutter GR. Health insurance affects the use of disease-modifying therapy in multiple sclerosis. Neurology. 2016 Jul 26;87(4):365-74. doi: 10.1212/WNL.0000000000002887. Epub 2016 Jun 29.</citation>
    <PMID>27358338</PMID>
  </reference>
  <reference>
    <citation>Salter A, Tyry T, Wang G, Fox RJ, Cutter G, Marrie RA. Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS. Neurol Clin Pract. 2016 Oct;6(5):397-408.</citation>
    <PMID>27847682</PMID>
  </reference>
  <reference>
    <citation>Salter A, Thomas N, Tyry T, Cutter G, Marrie RA. Employment and absenteeism in working-age persons with multiple sclerosis. J Med Econ. 2017 May;20(5):493-502. doi: 10.1080/13696998.2016.1277229. Epub 2017 Jan 25.</citation>
    <PMID>28035846</PMID>
  </reference>
  <reference>
    <citation>Reider N, Salter AR, Cutter GR, Tyry T, Marrie RA. Potentially Modifiable Factors Associated With Physical Activity in Individuals With Multiple Sclerosis. Res Nurs Health. 2017 Apr;40(2):143-152. doi: 10.1002/nur.21783. Epub 2017 Feb 6.</citation>
    <PMID>28165143</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Salter A, Tyry T, Cutter GR, Cofield S, Fox RJ. High hypothetical interest in physician-assisted death in multiple sclerosis. Neurology. 2017 Apr 18;88(16):1528-1534. doi: 10.1212/WNL.0000000000003831. Epub 2017 Mar 15.</citation>
    <PMID>28298551</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Cutter GR, Tyry T, Cofield SS, Fox R, Salter A. Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis. Mult Scler Relat Disord. 2017 Apr;13:87-92. doi: 10.1016/j.msard.2017.02.013. Epub 2017 Feb 20.</citation>
    <PMID>28427709</PMID>
  </reference>
  <reference>
    <citation>Salter A, Thomas NP, Tyry T, Cutter GR, Marrie RA. A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry. Mult Scler. 2017 May 1:1352458517711274. doi: 10.1177/1352458517711274. [Epub ahead of print]</citation>
    <PMID>28524746</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2009</study_first_submitted>
  <study_first_submitted_qc>November 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Amber Salter</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>NARCOMS</keyword>
  <keyword>Global Patient Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

